IMPROVED NANOBODIES AGAINST TUMOUR NECROSIS FACTOR-ALPHA Russian patent published in 2012 - IPC C07K16/24 C07K16/46 C12N15/13 C12N5/10 A61K39/395 A61P35/00 A61P37/00 A61P43/00 

FIELD: chemistry.

SUBSTANCE: disclosed is a nanobody against tumour necrosis factor-alpha (TNF-alpha) which has 4 framework regions FR and 3 HCDR. Described are versions of a nanobody-based polypeptide, each capable of binding with TNF-alpha. One version of such polypeptides contains at least one nanobody directed against human serum albumin. Corresponding coding nucleic acids are described. The invention also discloses a host cell for expression a nanobody and a host cell for expressing a polypeptide, each containing a corresponding nucleic acid; a method of producing a nanobody and a method of producing a nanobody-based polypeptide, where each of the methods employs the corresponding cell. Use of the nanobody to obtain a medicinal agent and a pharmaceutical composition against TNF-alpha are also discribed.

EFFECT: use of the invention provides a nanobody against TNF-alpha with high affinity, stability and suitability for production in multivalent format and low immunising power, which can be used in medicine to prevent, treat and diagnose TNF-alpha activity-mediated diseases.

80 cl, 62 dwg, 47 tbl, 65 ex